Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Intensive care for CAR-T: bridge to treatment and response

Michael von Bergwelt • 15 Mar 2019
ISAL 2019
General Leukemia CAR-T

The importance of intensive medicine in the management of patients treated with CAR T-cells should not be underestimated. Speaking from the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany, Michael von Bergwelt, MD, PhD, of LMU Hospital Munich, Munich, Germany, discusses the importance of intensive care in this field, highlighting the capacity, resources and training issues that need to be addressed.

More from Michael von Bergwelt

2:25
Increase in cancer patient transfers to the ICU: what does it come down to?
Michael von Bergwelt • 10 Jul 2019
2:33
EuroCARTForce: a platform for progress
Michael von Bergwelt • 10 Jul 2019
1:14
Preparing the critical care workforce for CAR-T
Michael von Bergwelt • 10 Jul 2019
3:43
Learnings from a CAR-T center: leukapheresis, bridging therapy, toxicities & more
Michael von Bergwelt • 15 Mar 2019

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
The content of VJHemOnc is intended for healthcare professionals